Claritev (NYSE:CTEV) Rating Increased to Hold at Zacks Research

Posted by Geri Gentry on Aug 15th, 2026

Claritev (NYSE:CTEV – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other equities research analysts have also recently commented on CTEV. Wells Fargo & Company upped their price target on Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research report on Wednesday. Canaccord Genuity Group boosted their price objective on shares of Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Finally, Barclays started coverage on shares of Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 target price for the company. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Check Out Our Latest Analysis on CTEV

Claritev Trading Down 8.8%

Claritev stock opened at $38.51 on Thursday. Claritev has a twelve month low of $11.50 and a twelve month high of $74.07. The stock has a 50 day moving average of $29.85 and a two-hundred day moving average of $24.05. The stock has a market capitalization of $652.74 million, a price-to-earnings ratio of -2.26 and a beta of 0.74.

Insider Buying and Selling at Claritev

In related news, SVP William B. Mintz sold 8,431 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $34.24, for a total transaction of $288,677.44. Following the transaction, the senior vice president owned 71,195 shares of the company’s stock, valued at $2,437,716.80. This represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Claritev

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming acquired a new position in shares of Claritev during the 4th quarter worth $25,000. Public Employees Retirement System of Ohio purchased a new stake in Claritev during the first quarter worth about $38,000. Ameritas Investment Partners Inc. purchased a new stake in Claritev during the third quarter worth about $42,000. Legal & General Group Plc acquired a new position in Claritev during the third quarter worth about $45,000. Finally, Los Angeles Capital Management LLC purchased a new position in Claritev in the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 87.15% of the company’s stock.

Claritev Company Profile

(Get Free Report)

Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.